Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes

被引:23
|
作者
Snoeck, J
Riva, C
Steegen, K
Schrooten, Y
Maes, B
Vergne, L
Van Laethem, K
Peeters, M
Vandamme, AM
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
[2] Univ Milan, Inst Infect & Trop Dis, Milan, Italy
[3] Univ Hosp Montpellier, Dept Virol, Montpellier, France
[4] Univ Hosp Montpellier, Dept Infect Dis, Montpellier, France
[5] Inst Rech & Dev, Retrovirus Lab, UR036, Montpellier, France
[6] Katholieke Univ Leuven Hosp, AID Reference Lab, Louvain, Belgium
关键词
genotypic assay; RNase H region; non-B subtypes; gag cleavage sites;
D O I
10.1016/j.jviromet.2005.04.001
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Genotypic assays are used often to guide clinicians in decisions concerning the treatment of patients. An optimized sequence-based genotypic assay was used to determine the whole protease and reverse transcriptase (RT) gene, including the gag cleavage site region and RNase H region. Since non-B subtypes are increasing in countries where subtype B was the most prevalent Subtype, and treatment becomes more available in developing countries where the epidemic is characterized by a high prevalence of non-B subtypes, it was important that the genotypic test was evaluated using a panel of different subtypes. Amplification was successful for different subtypes: A, B, C, D, F, G, H, J, CRF01_AE, CRF02-AG, CRF11-cpx, CRF13-cpx and an uncharacterized recombinant sample. The detection limit of the PCR was 1000 copies/ml, except for 1 subtype C sample (PL3) and 1 CRF02_AG sample (PL8). The detection limit for these samples was 5000 copies/ml. A sequence could be obtained in both directions for most of the samples. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:47 / 53
页数:7
相关论文
共 50 条
  • [21] Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing
    Rhee, SY
    Liu, T
    Ravela, J
    Gonzales, MJ
    Shafer, RW
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) : 3122 - 3126
  • [22] Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: Clinical impact and molecular mechanisms
    Winters, MA
    Merigan, TC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) : 2575 - 2582
  • [23] Intra patient evolution of Human Immunodeficiency Virus Type 1 protease and reverse transcriptase in antiretroviral naive patients
    Shanmugasundaram, Uma
    Nagalingeswaran, Kumarasamy
    Murugavel, Kailapuri G.
    Shanmugam, Saravanan
    Madhavan, Vidya
    Solomon, Sunil S.
    Solomon, Suniti
    Mayer, Kenneth H.
    Pachamuthu, Balakrishnan
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 : 185 - 185
  • [24] Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent
    Snoeck, J
    Kantor, R
    Shafer, RW
    Van Laethem, K
    Deforche, K
    Carvalho, AP
    Wynhoven, B
    Soares, MA
    Cane, P
    Clarke, J
    Pillay, C
    Sirivichayakul, S
    Ariyoshi, K
    Holguin, A
    Rudich, H
    Rodrigues, R
    Bouzas, MB
    Brun-Vézinet, F
    Reid, C
    Cahn, P
    Brigido, LF
    Grossman, Z
    Soriano, V
    Sugiura, W
    Tanuri, A
    Harrigan, RP
    Camacho, R
    Schapiro, JM
    Katzenstein, D
    Vandamme, AM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) : 694 - 701
  • [25] Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target
    Srivastava, S.
    Sluis-Cremer, N.
    Tachedjian, G.
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (15) : 1879 - 1894
  • [26] A highly sensitive chemiluminescent reverse transcriptase assay for human immunodeficiency virus
    Odawara, F
    Abe, H
    Kohno, T
    Nagai-Fujii, Y
    Arai, K
    Imamura, S
    Misaki, H
    Azuma, H
    Ikebuchi, K
    Ikeda, H
    Mohan, S
    Sano, K
    JOURNAL OF VIROLOGICAL METHODS, 2002, 106 (01) : 115 - 124
  • [27] Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
    de la Carrière, LC
    Paulous, S
    Clavel, F
    Mammano, F
    JOURNAL OF VIROLOGY, 1999, 73 (04) : 3455 - 3459
  • [28] Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations
    Monno, L
    Appice, A
    Cavaliere, R
    Scarabaggio, T
    Angarano, G
    JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02): : 568 - 570
  • [29] Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer
    Wapling, J
    Moore, KL
    Sonza, S
    Mak, J
    Tachedjian, G
    JOURNAL OF VIROLOGY, 2005, 79 (16) : 10247 - 10257
  • [30] ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase
    Naeger, LK
    Margot, NA
    Miller, MD
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (07) : 2179 - 2184